Nemonoxacin

Summary

Nemonoxacin (CHEMBL1213456) is a phase-3 clinical-stage small molecule (ATC J01MB08); indicated across 6 conditions including pneumonia and bacterial pneumonia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01MB08
• Indications: 6 conditions
• Clinical trials: 10
• Chemistry: 371.4 Da · C20H25N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213456
Name	Nemonoxacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11993740
ATC	J01MB08
Molecular formula	C20H25N3O4
Molecular weight	371.4
InChIKey	AVPQPGFLVZTJOR-RYUDHWBXSA-N

SMILES: C[C@H]1C[C@@H](CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N

IUPAC name: 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid

Also known as: Nemonoxacin, Nemonoxacine, Nemonoxacino, TG-873870, nemonoxacin, NEMONOXACIN

Parent form; salt/anhydrous children: CHEMBL1213283

Patent coverage: 104 distinct patent families (255 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 252 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
kidney disorder	1	MONDO:0005240	EFO:0003086
liver disorder	1	MONDO:0005154	HP:0001410

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	3
PHASE1	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05133752	PHASE4	COMPLETED	Oral Nemonoxacin in Treating Elderly Patients With CAP
NCT01529476	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP
NCT02205112	PHASE3	COMPLETED	A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
NCT03551210	PHASE3	COMPLETED	Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
NCT00685698	PHASE2	COMPLETED	Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
NCT01537250	PHASE2	COMPLETED	Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)
NCT01944774	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride
NCT01395108	PHASE1	COMPLETED	Clinical Study on Oral Nemonoxacin Malate Capsules
NCT02604498	PHASE1	COMPLETED	Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
NCT02840812	PHASE1	UNKNOWN	Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).